{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "hmdb:HMDB06564",
      "entity_text" : "glucose",
      "entity_type" : "simple_chemical"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ00085",
      "entity_text" : "SGLT2 inhibitors",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Because no previous study to our knowledge has comprehensively characterized the changes in renal glucose handling through which SGLT2 inhibitors augment renal glucose excretion in humans, the current study was undertaken to examine the mechanisms through which dapagliflozin produces its glucosuric effect in individuals with type 2 diabetes and those with normal glucose tolerance.",
  "reading_complete" : "2020-07-28T11:26:48Z",
  "reader_type" : "machine",
  "reading_started" : "2020-07-28T11:21:12Z",
  "trigger" : "augment",
  "evidence" : [ "SGLT2 inhibitors augment renal glucose" ],
  "pmc_id" : "3781504",
  "score" : 0
}